Routine cancer screenings are vital for early detection and prevention of more invasive cancers, which improves treatment outcomes and reduces mortality rates significantly. For individuals at average risk, routine cancer screenings facilitate the identification of preclinical cancer or precancerous lesions. In some cases, they enable timely interventions, reducing the risk of advanced-stage diagnoses, which are associated with poorer clinical outcomes. Despite endorsements from multiple advisory bodies for colorectal cancer screening (CRCS), lung cancer screening (LCS), breast cancer screening (BCS), and cervical cancer screening (CCS), the rates among eligible adults in the US remain below recommended targets.
1 Furthermore, significant disparities in evidence-based screening adherence persist, disproportionately affecting structurally marginalized populations.
2,3 These disparities, rooted in a complex interplay of factors exacerbated by longstanding structural inequities and societal injustices, pose a substantial challenge to public health and impede progress toward achieving health equity.
4